Loading
NYSEHealthcareDrug Manufacturers - General
Latest quote
$271.36
+$4.67 · +1.75%
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Latest quote
$271.36
+$4.67 · +1.75%
After-hours
$272.55
+$1.19 · +0.44%
Oct 7, 7:47 PM ET
Regular session · ET · Market data may be delayed.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Day range
Current $271.36
52-week range
Current $271.36
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
18
Overpriced
Sentiment
70
Bullish
Risk
19
Low Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Day range
Current $271.36
52-week range
Current $271.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 61.16B USD | 56.33B USD | 54.32B USD | 58.05B USD | 56.2B USD |
| Cost of goods sold | 18.2B USD | 16.9B USD | 20.42B USD | 17.41B USD | 17.45B USD |
| Gross profit | 42.96B USD | 39.43B USD | 33.9B USD | 40.64B USD | 38.75B USD |
| Research and development | 9.1B USD | 12.79B USD | 7.68B USD | 6.51B USD | 8.05B USD |
| Selling, general, and administrative | 14.01B USD | 14.75B USD | 12.87B USD | 15.26B USD | 12.35B USD |
| Operating expenses | 22.87B USD | 30.29B USD | 21.15B USD | 22.52B USD | 20.83B USD |
| Interest income | 266M USD | 648M USD | 540M USD | 186M USD | 39M USD |
| Interest expense | 2.89B USD | 2.81B USD | 2.22B USD | 2.23B USD | 2.42B USD |
| Depreciation and amortization | 8.14B USD | 8.39B USD | 8.7B USD | 8.47B USD | 8.52B USD |
| Operating income | 20.09B USD | 9.14B USD | 12.76B USD | 18.12B USD | 17.92B USD |
| Net income | 4.23B USD | 4.28B USD | 4.86B USD | 11.84B USD | 11.54B USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$290.43
7.03% upsideCash distributions grouped by calendar year; partial years are marked.
$6.56
2025 complete year+26.2% since 2021
2026 partial: $5.19
$5.20
2,021
$5.64
2,022
$5.92
2,023
$6.20
2,024
$6.56
2,025
$5.19
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Oct 15, 2026 | $1.73Quarterly | Oct 15, 2026 | Nov 16, 2026 |
Dividend | Jul 15, 2026 | $1.73Quarterly | Jul 15, 2026 | Aug 14, 2026 |
Dividend | Apr 15, 2026 | $1.73Quarterly | Apr 15, 2026 | May 15, 2026 |
Dividend | Jan 16, 2026 | $1.73Quarterly | Jan 16, 2026 | Feb 17, 2026 |
Dividend | Oct 15, 2025 | $1.64Quarterly | Oct 15, 2025 | Nov 14, 2025 |
Dividend | Jul 15, 2025 | $1.64Quarterly | Jul 15, 2025 | Aug 15, 2025 |
Ex-dividend Oct 15, 2026
$1.73
Quarterly
Record Oct 15, 2026 · Payment Nov 16, 2026
Ex-dividend Jul 15, 2026
$1.73
Quarterly
Record Jul 15, 2026 · Payment Aug 14, 2026
Ex-dividend Apr 15, 2026
$1.73
Quarterly
Record Apr 15, 2026 · Payment May 15, 2026
Ex-dividend Jan 16, 2026
$1.73
Quarterly
Record Jan 16, 2026 · Payment Feb 17, 2026
Ex-dividend Oct 15, 2025
$1.64
Quarterly
Record Oct 15, 2025 · Payment Nov 14, 2025
Ex-dividend Jul 15, 2025
$1.64
Quarterly
Record Jul 15, 2025 · Payment Aug 15, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T906.91B0.70%129.41T JPY0.09%¥123,000-0.32%
Vanguard Morningstar Total Stock Market ETFVTI14.4B0.61%2.3T USD0.03%$381.03-0.40%
Vanguard S&P 500 ETFVOO12.04B0.68%1.8T USD0.03%$714.34-0.26%
iShares Core S&P 500 ETFIVV6.28B0.70%899.63B USD0.03%$780.58-0.25%
State Street SPDR S&P 500 ETFSPY5.73B0.70%819.04B USD0.09%$777.22-0.24%
Vanguard Morningstar Value ETFVTV4.33B1.65%262.4B USD0.03%$218.21-0.37%
State Street Health Care Select Sector SPDR ETFXLV3.35B7.76%43.11B USD0.08%$168.81+1.03%
Vanguard Dividend Appreciation ETFVIG2.56B1.93%132.4B USD0.04%$236.99-0.32%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVVanguard Dividend Appreciation ETFVIGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
